Health Canada Approves Use of Gilead’s Remdesivir to Treat COVID


Health Canada on Tuesday cleared the use of Gilead Sciences Canada Inc.’s remdesivir to treat people with severe symptoms of COVID-19, making it the first drug approved by the regulatory body to treat the virus.The use of remdesivir is only allowed under certain conditions, Health Canada said. It has been approved for use in adults and adolescents 12 years of age or older.

Other conditions of Health Canada include that the manufacturer ensures the continued safety, efficacy and quality of the drug. The regulator has said it will closely monitor how remdesivir is prescribed to patients and take action if there is a problem.

“We appreciate Health Canada’s expedited review of Veklury (the brand name for remdesivir) in recognition of the urgent need to treat patients with COVID-19 in Canada,” said Gilead Sciences Canada CEO Melissa Koomey , in a statement Tuesday. “We are grateful for their collaboration and leadership as we work together to respond to this public health emergency. ”

The drug has received emergency or conditional clearance in some other countries, including the United States, Japan, Europe and Australia.

In Canada, some patients with COVID-19 have already been treated with remdesivir under the regulator’s special access program.


Please enter your comment!
Please enter your name here